GIBSON DUNN

Gibson Dunn Advises Ultragenyx on $400 Million Sale of a Portion of Future North American Royalties on Crysvita® (burosumab)

Firm News | November 5, 2025

Gibson Dunn is advising Ultragenyx Pharmaceutical Inc. on its sale of a portion of future North American royalties on Crysvita® (burosumab) for $400 million.

Gibson Dunn regularly advises life sciences companies on complex royalty monetization and strategic transactions in the biopharmaceutical sector.

The Gibson Dunn corporate team is led by Ryan Murr and Karen Spindler and includes George Hang. Pamela Lawrence Endreny and Ryan Rott are advising on tax aspects.

Related People

Ryan A. Murr

Karen A. Spindler

George Hang

Pamela Lawrence Endreny

Ryan Rott

Related Capabilities

Mergers and Acquisitions

Life Sciences

Tax

Technology Transactions

Intellectual Property

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**